An analysis published in JAMA Internal Medicine in 2022 found that patients using GLP-1 receptor agonists had a higher incidence of gallbladder-related events compared to those using other diabetes medications
While GLP-1 receptor agonist therapy leads to greater relative fat loss than lean mass loss, preserving muscle tissue requires adequate protein intake and resistance exercise during weight reduction
This can slow or reverse fatty liver disease, which is common in people with obesity
In general, gastrointestinal side effects, especially constipation, may persist even as other symptoms diminish over time and appear to occur less frequently with long-acting GLP-1 RAs [118]
Targets stubborn fat: Works on belly fat, love handles, and thighs
It is also not advised for those with severe gastrointestinal disease or with hypersensitivity to semaglutide or any of its components